IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Alembic Completes Acquisition of Dabur Pharma

1:31 PM MDT | July 24, 2007 | DR

Pharmaceutical company Alembic (Vadodara, India) says it has completed the acquisition of the non-oncology formulation business of Dabur Pharma (New Delhi) for approximately $37 million. Alembic acquired full rights to market 24 Dabur brands, under the terms of the deal. Most of the brands are in the high-growth lifestyle therapeutic segments of cardiology, diabetology, and gynecology. Alembic is the largest player in the anti-infective drug segment in India, and aims to increase market share in the lifestyle segment. “With this acquisition, we have a ready...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa